An established drug for recurrent multiple myeloma might effectively be repurposed to improve the survival and day-to-day lives of patients with devastating sickle cell disease, according to revealing new research by a Feinstein Institute for Medical Research scientist.
The study, by Lionel Blanc, PhD, an assistant investigator at the Feinstein Institute, will be published Dec. 17 in the journal Blood. Dr. Blanc’s research, performed in collaboration with the New York Blood Center, Yale School of Medicine and University of Montpellier in France, was the first to identify how the drug pomalidomide increases production of fetal hemoglobin, known to interfere with the so-called “sickling” of red blood cells implicated in sickle cell disease (SCD).
Illuminating pomalidomide’s mechanism of action offers proof of concept that the US Food and Drug Administration (FDA)-approved medication could potentially be used to treat SCD, representing better outcomes compared to current drug treatment for the 100,000 Americans with SCD, an inherited disorder causing poor oxygen delivery, organ damage and even death.
“We knew the drug would make fetal hemoglobin, but we didn’t know to what extent or how. That was the goal of the study,” explained Dr. Blanc, also an assistant professor of molecular medicine and pediatrics at Hofstra North Shore-LIJ School of Medicine and an Allied World St. Baldrick’s Scholar.
“We can also say something else – that hydroxyurea, the only FDA-approved drug for sickle cell anemia, was less effective than pomalidomide and appeared to act through a different mechanism of action,” he added. “The current therapy is good, but not everyone responds equally to hydroxyurea, and what we hope with pomalidomide is to improve this.”
Pomalidomide, a derivative of thalidomide used in advanced cases of the cancer multiple myeloma, works by killing malignant plasma cells. But Dr. Blanc and his colleagues demonstrated in the new research, performed on stem cells taken from five SCD patients and 120 normal controls, how pomalidomide also generated fetal hemoglobin, the fetal version of the protein in red blood cells that carries oxygen to body tissues.
In patients with congenital conditions producing anemia such as SCD and beta-thalassemia, fetal hemoglobin is normal, but adult hemoglobin – produced after birth – is abnormal. Therefore, reversing their production of adult hemoglobin back to fetal hemoglobin can reverse the course of their disease.
In addition to the 100,000 US residents with SCD, the condition also affects millions globally. “I would remind people that anemia impacts 1.6 billion people worldwide, making it a global economic burden,” Dr. Blanc notes.
Dr. Blanc and his colleagues in the Division of Hematology/Oncology at Cohen Children’s Medical Center of New York plan to launch a clinical trial in the near future in collaboration with other institutions to test pomalidomide, which is taken orally, in young adults with SCD.
Currently, the only potential cures for SCD are gene therapy, still in the experimental stage, or stem cell transplant, but these resource-intense treatments aren’t available to the vast majority of patients, particularly in the developing world.
“Our hope is to alleviate the symptoms of sickle cell disease by using a pill that could be made available to almost all patients, worldwide,” Dr. Blanc said.
The Latest on: Sickle Cell Disease
via Google News
The Latest on: Sickle Cell Disease
- Santonio Holmes Back In Pittsburgh, Raising Awareness About Sickle Cell Diseaseon October 9, 2020 at 1:48 pm
Former Pittsburgh Steelers wide receiver Santonio Holmes is back in Pittsburgh. He’s hosting the fourth annual Strikes Against Sickle Cell Bowling event this weekend. While the event went virtual this ...
- Sickle cell disease is challenging but not insurmountable for son of Lakeland commissioneron October 6, 2020 at 2:12 pm
Lakeland resident Christian Walker, the son of Commissioner Philip Walker, has battled sickle cell disease for 20 years. Christian now is on a drug called hydroxyurea to reduce his need for ...
- Options for treating sickle cell disease expanded last fallon October 6, 2020 at 1:43 pm
Two new therapy options won Food and Drug Administration approval within 10 days of each other in November 2019, blooms of hope in what has been a relatively unchanging landscape. Adakveo, approved ...
- $7.1M grant to review opioid alternatives to treating sickle cell disease painon October 6, 2020 at 12:01 pm
Researchers at the University of Illinois Chicago will lead a $7.1 million, five-year national study to determine the effectiveness of acupuncture and guided relaxation for people with chronic pain ...
- FDA Grants GlycoMimetics Rare Pediatric Disease Designation for Rivipansel for Treatment of Sickle Cell Diseaseon October 5, 2020 at 1:34 pm
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company a Rare Pediatric Disease designation for rivipansel for the treatment of ...
- Sickle cell disease didn't stop Lakesha Dickerson — it inspired her to become a nurseon October 5, 2020 at 6:00 am
Growing up with sickle cell disease, Lakesha Thomas Dickerson essentially spent her childhood in doctors’ offices and hospitals.
- The FDA Should Approve New Treatments for Sickle Cell Patientson October 2, 2020 at 6:08 am
It’s been decades since the FDA has approved new treatments for the benefit of patients with sickle cell disease.”Sonya L. Banks, president of the Sickle Cell Disease Association of America ...
- Approximately 40 percent of babies born with sickle cell disease in Texas are in Houstonon October 1, 2020 at 3:07 pm
There are about 180 babies born with sickle cell disease in Texas each year, and approximately 40 percent (70 children) are born in Houston. The Houston Health Department said in a press release that ...
- Aflac Contributes $1.5 Million to Sickle Cell Disease Program at the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlantaon September 30, 2020 at 1:30 pm
September is National Sickle Cell Awareness Month, and Aflac, a leader in supplemental insurance sales at U.S. worksites, today announced ...
- Life as a sickle cell warrior: How advocates are changing the face of the diseaseon September 30, 2020 at 12:29 pm
sickle cell advocate Shamonica Wiggins shares with theGrio. Sickle cell disease (SCD) is a group of red blood cell disorders occurring when a child inherits the sickle cell gene from both parents ...
via Bing News